Roche pays $2.4B for rest of cancer expert Foundation Medicine

Tue, 19 Jun 2018 - 08:26 GMT

The deal is worth $137 per share - a premium of 29 percent to FMI’s closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion.